Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Merck's sac-TMT Phase 3 win is the most important ADC data point since Enhertu's early breast cancer approval last week. The endometrial cancer readout shows sacituzumab tirumotecan significantly improved both PFS and OS versus chemotherapy, validating the Trop-2 target in a new tumor type and giving Merck a registrational-quality dataset for a future filing. This is exactly the kind of asset Merck needs as it builds the post-Keytruda portfolio. The Kelun-Biotech partnership, which gives Merck global rights outside China, is now one of the most productive China licensing deals in the industry alongside BMS/Hengrui ($15.2B) and Lilly/Hengrui (via Kailera). Meanwhile, the ASCO countdown is officially on. Truist projected a Q3 2026 approval for Revolution Medicines' daraxonrasib, which would make it one of the fastest oncology drugs from Phase 3 readout to market in recent memory. The company plans to file under the CNPV program. If the 50-day Foundayo precedent holds, an August or September approval is plausible. Brian Wolpin presents the full RASolute 302 dataset at the ASCO plenary on May 31. Eleven days. 👉 Read Full Analysis

Merck's sac-TMT Hits Phase 3 in Endometrial Cancer MRK

What Happened: Merck reported positive Phase 3 results for sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate co-developed with China's Kelun-Biotech, in advanced or recurrent endometrial cancer. The drug significantly improved both progression-free survival and overall survival versus investigator's choice chemotherapy. The Pharma Letter called it "a potentially important new growth driver as it prepares for future competition to blockbuster immunotherapy Keytruda." BioSpace noted the companies "have yet to specify when they plan to file for approval."

The Asset: sac-TMT targets Trop-2, the same antigen targeted by Gilead's Trodelvy (sacituzumab govitecan), but uses a different linker-payload combination (tirumotecan payload). The differentiation is in the payload chemistry: tirumotecan is designed to deliver a more potent cytotoxic effect with a potentially improved therapeutic window. Kelun-Biotech developed the molecule and licensed global rights (outside China) to Merck.

Executive Impact: This win validates three converging trends. First, ADCs continue to expand beyond breast cancer into new tumor types (endometrial, after Enhertu's early breast cancer approval last week). Second, the China licensing model continues to produce registrational-quality assets (BMS/Hengrui, Lilly/Hengrui, GSK/SiranBio, AbbVie/Haisco, and now Merck/Kelun-Biotech). Third, Merck's post-Keytruda pipeline build is producing results. The company needs multiple growth drivers to offset the 2028 LOE, and sac-TMT in endometrial cancer plus the broader Kelun-Biotech ADC collaboration give it a franchise-level opportunity in the ADC space.

Truist Projects Revolution Medicines Approval by End of Q3 RVMD

Truist Securities issued a note calling Revolution Medicines a company that "is evolving into a major revenue-generating oncology company" and projected an FDA approval for daraxonrasib in second-line pancreatic cancer by the end of Q3 2026, according to BioSpace. If Revolution files under the CNPV program (as planned), the 50-day Foundayo precedent suggests approval could come within weeks of filing. Full Phase 3 data will be presented at the ASCO plenary on May 31, 11 days from today. A month after the Phase 3 readout, Truist said the company has moved from a clinical-stage biotech to "a major revenue-generating oncology company" in the eyes of the Street.

Regeneron Partners with Parabilis on Antibody-Helicon Conjugates REGN

Regeneron announced a strategic research collaboration with Parabilis Medicines to develop Antibody-Helicon Conjugates (AHCs), a novel therapeutic class combining antibodies with Parabilis's Helicon peptide platform to target historically undruggable proteins. The Pharma Letter noted the focus on "challenging and historically 'undruggable' targets." BioSpace reported the deal came "right after reporting a major Phase 3 LAG-3 miss" in melanoma, suggesting Regeneron is diversifying its pipeline after the fianlimab setback.

FDA Accepts Asundexian NDA for Stroke Prevention

The FDA and Japan's Ministry of Health accepted New Drug Applications for asundexian, an investigational Factor XIa (FXIa) inhibitor, for prevention of ischemic stroke in patients after non-cardioembolic ischemic stroke or transient ischemic attack, according to The Pharma Letter. Factor XIa inhibitors represent a new class of anticoagulants designed to reduce stroke risk without the bleeding complications associated with current therapies. If approved, asundexian would be the first Factor XIa inhibitor on the market and could challenge Eliquis and Xarelto in specific patient populations.

Ethics Disclosure: Trump Stock Purchases Include Lilly

Federal ethics disclosures released May 14 show that stock purchases of up to $680,000 in Eli Lilly and up to $500,000 in West Pharmaceutical Services (a GLP-1 injectable device manufacturer) were made on President Trump's behalf between January and March 2026. The purchases were part of broader trades across the economy including tech, aerospace, and consumer companies. The Trump Organization has said in the past that neither the president nor his children play a role in "selecting, directing, or approving" specific investments. The disclosure was first reported by KFF Health News.

👉 Read Full Analysis

Merck faces one of the largest single-product patent cliffs in pharma history. Keytruda, the world's best-selling drug, faces LOE in 2028. The company has been systematically building an ADC portfolio through its Kelun-Biotech partnership:

The sac-TMT data validates Merck's China licensing strategy. Kelun-Biotech developed the molecule at lower cost, Merck gets global commercial rights, and both companies share the economics. This is the same playbook as BMS/Hengrui ($15.2B, 13 programs), Lilly/Hengrui (Kailera obesity franchise), GSK/SiranBio ($1B ALK7), and AbbVie/Haisco (Nav1.8 pain).

If sac-TMT is approved, it would compete directly with Gilead's Trodelvy in the Trop-2 space. The differentiation is in payload chemistry: tirumotecan (sac-TMT) vs. SN-38 (Trodelvy). Head-to-head clinical comparisons do not exist, but the endometrial cancer data positions sac-TMT as a best-in-class candidate in at least one tumor type.

💊 ASCO Countdown: 11 Days

The May 31 plenary session is the most anticipated oncology presentation of 2026. What we know:

Truist's Q3 approval projection implies Revolution files under CNPV shortly after the ASCO presentation. If CNPV review mirrors the Foundayo precedent (50 days), an August or September 2026 approval is plausible. Revolution has approximately $4B in cash (after the $2.2B offering), sufficient to self-fund commercialization.

The ASCO presentation will determine whether the investment thesis transitions from "promising data" to "imminent commercial launch."

📊 Factor XIa: The Next Cardiovascular Frontier

Current oral anticoagulants (Eliquis, Xarelto) work by inhibiting Factor Xa or thrombin. They reduce stroke risk but carry significant bleeding risk, which limits their use in some patient populations.

Factor XIa inhibitors represent a fundamentally different approach. Factor XI sits higher in the coagulation cascade and is more closely linked to pathological clot formation (thrombosis) than to normal bleeding (hemostasis). Inhibiting Factor XIa should, in theory, reduce thrombotic events while preserving the body's ability to stop bleeding.

If asundexian's NDA review confirms this profile, the drug could capture share from Eliquis and Xarelto in stroke prevention, particularly in patients who cannot tolerate bleeding risk. The Eliquis patent cliff (98.6% projected revenue collapse by 2031) creates additional commercial opportunity for a differentiated successor.

🎯 Catalyst Calendar: May 2026 Forward

👉 Visit The Pro Hub

Limited ASCO-week sponsorship slots available (May 29 - June 2). Reach 65,000+ professionals during the biggest oncology event of the year. Learn more →

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →